cancer progress conference new york city
play

Cancer Progress Conference New York City Michael B. Sporn, MD - PowerPoint PPT Presentation

Cancer Progress Conference New York City Michael B. Sporn, MD Professor of Pharmacology and Medicine Dartmouth Medical School May 7, 2019 Statement Michael Sporn is the founder of a new company, Triterpenoid Therapeutics, whose goal is to


  1. Cancer Progress Conference New York City Michael B. Sporn, MD Professor of Pharmacology and Medicine Dartmouth Medical School May 7, 2019

  2. Statement Michael Sporn is the founder of a new company, Triterpenoid Therapeutics, whose goal is to introduce new synthetic triterpenoids into clinical use.

  3. Projected Huge Increase in Pancreatic Cancer Deaths, USA 2010 --- 37,000 Deaths, actual 2030 --- 63,000 Deaths, projected • Pancreatic Cancer is projected to be the second leading cause of cancer deaths in the USA by 2030 Rahib, L., Cancer Res 74: 2913-2921 (2014)

  4. Concept 1 The disease is carcinogenesis, not cancer • Carcinogenesis is a process , not a state

  5. Process of Carcinogenesis Progression takes many years B. Vogelstein, et al. Science 339, 1546, 2013

  6. Progression Model for Pancreatic Cancer Normal PanIN-1A PanIN-1B PanIN-2 PanIN-3 Her-2/neu p16 P53 K-rus DPCA BRCA2 LOH 9P LOH 18q, 17p, 6q Progression model for pancreatic cancer. The progression from histologically normal epithelium to low-grade PanIN to high-grade PanIN (left to right) is associated with the accumulation of specific genetic alterations (Hruban et al., Am. J. Pathol ., 156:1821, 2000)

  7. Cancer is a polygenic disease • Pancreatic cancers contain an average of 63 genetic alterations Science , 321, 1801, 2008

  8. Concept 2 People who are asymptomatic may not be healthy

  9. The concept of ‘health’ needs to consider future events, not just the immediate present

  10. Concept 3 Use of drugs to suppress carcinogenesis during the latency period after mutagenic initiation

  11. Chemoprevention Works!!!!!

  12. Arzoxifene and LG100268 Synergize in Prevention of ER- Negative Mammary Gland Tumors in MMTV-neu Mice 100 (16) Percent of mice with tumors Control 75 Arzoxifene (8) (20 mg/kg diet) 50 LG100268 (30 mg/kg diet) (8) Combination 25 (8) 0 20 25 30 35 40 45 50 55 60 Weeks on diet MMTV-neu transgenic mice (Jax Labs) were fed powdered control diet or preventive agents in the same diet, beginning at 7 weeks of age. Mice (numbers shown in parentheses) were palpated weekly for tumors, and none were detected before 20 weeks of age. The experiment was terminated after mice were fed experimental diets for 60 weeks. Liby et al. , Clin. Cancer Res. 12: 5902, 2006

  13. Cancer Complete Protection against Aflatoxin B 1 -Induced Liver Cancer with a Preventi Triterpenoid: DNA Adduct Dosimetry, Molecular Signature, and on Genotoxicity Threshold Researc h Natalie M. Johnson, Patricia A. Egner, Victoria K. Baxter, Michael B. Sporn, Ryan S. Wible, Thomas R. Sutter, John D. Groopman, Thomas W. Kensler, and Bill D. Roebuck Cancer Prev Res ; 7 July 2014

  14. Complete Prevention of Liver Cancer in Rats by CDDO-Im

  15. Concept 8 Chemopreventive drugs may function more effectively if dosed intermittently rather than continuously

  16. A new paradigm for chemoprevention Carcinogen Autopsy Control Diet Chemopreventive agents in diet, at high doses that induce apoptosis M. Rendi, N. Suh, et al ., Cancer Res. 64 : 3566, 2004

  17. What we need to do

  18. • New Ideas • New Diagnostic Tools • New Drugs

  19. • The Old DNA RNA Protein Model is obsolete • A New World of Network Biology

  20. Fantasy and Fact in Signaling It Ain’t So The Real World Levy et al., Science 328, 983, 2010

  21. New Diagnostic Tools • Genomic • Proteomic • Metabolomic These will identify people at super high risk These will be highly profitable for Pharmas

  22. New Drugs

  23. Triterpenoid Scaffolds (birch bark) (apples) (olives) (ginseng) (cork)

  24. Oleanane Triterpenoid Drugs O O CO 2 Me COOH NC NC CDDO CDDO-Me O O H H CDDO-Methyl ester O O N N CONHCH 2 CH 3 NC NC O CDDO-EA O CDDO-Im O H CDDO-Ethyl amide H CDDO-Imidazolide Liby, Sporn Pharmacol Revs 2012.

  25. Triterpenoids and suppression of inflammation

  26. Potency of Triterpenoids CDDO-Im Suppresses iNOS Induction in Macrophages 120 FemtoMolar Activity of CDDO-Im CDDO CDDO-Me CDDO-Im 100 TGF-beta 80 60 40 20 0 Concentration (Log M) -17 -16 -15 -14 -13 -12 -11 -10 -9 -8 -7 -6

  27. To Upset the Apple Cart

  28. “Cancer is Fundamentally an Epigenetic Disease”

  29. “The Key Role of Epigenetics in Human Disease Prevention and Mitigation” A.P. Feinberg, N Eng J Med 378, 1323 (2018)

  30. Paul Talalay

Recommend


More recommend